Article
Tom Caravela
The Ideal Roadmap for New MSLs
Summary
In this episode, Tom Caravela is joined by Sarah Snyder, MSL Recruiter at The Carolan Group and Co-Founder of MSL Mastery who discusses an ideal road map for new Medical Science Liaisons (MSLs). They walk through the 4 stages of what a new MSL experiences in the first full year. Building the foundation in months 1 to 3, Gaining momentum in months 3-6, becoming a trusted partner in months 6-12 and driving impact/delivering results at the 1 year mark and beyond. They also discuss tools and resources for enhancing MSL career progression and development. The episode explores personal branding, social media presence, and future trends in digital as well as AI for MSLs.
Key Points
- Establishing a well-organized home office and staying updated in your therapeutic area is crucial for new MSLs to hit the ground running.
- Building a strong foundation through structured training and certification is essential in the initial months to set the stage for becoming a trusted partner in the field.
- Personal branding and maintaining a professional digital presence on platforms like LinkedIn are increasingly important for career advancement and networking as an MSL.
Medical Science Liaisons, MSL career progression, personal branding, digital presence, MSL training
Related Topics
You May Also Like
Tom Caravela
Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Social Media Listening Evolved
Podcast
MSL Talk: Tom Caravela
How to Start Presenting Like a Pro
Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS